Type and hit ENTER

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing client list of pharmaceutical companies and academic laboratories.

ProAxsis specialises in four key areas of business:

ProteaseTag®
Active Neutrophil Elastase Immunoassay
  • Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.
NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
services for both academic and pharmaceutical company researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProteaseTag® immunoassay - Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Clinical research services

Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

R&D Projects

ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

  • Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

 

  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

 

  • Clinical research services – Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

 

  • R&D Projects – ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners.  We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProAxsis are delighted to announce that the company will be presenting results from several recent projects at the European Respiratory Society (ERS) annual conference, taking place in virtual format from the 5th-9th September.  Three e-posters will be presented by Dr Darragh McCafferty, the company’s Head of Assay …

September 3, 2021

York and Belfast, UK (August 19th, 2021) – Aptamer Group, the developer of custom affinity ligands to enable the life science industry through its proprietary OptimerTM platform, and ProAxsis Limited, a commercial-stage respiratory diagnostics company, today announce a partnership to develop Optimer ligands for ProAxsis’s diagnostic assays. …

August 19, 2021

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce two new appointments within its commercial team.  Nina Morrison joins the company as Business Development Manager.  Nina brings a wealth of field-based commercial experience to ProAxsis, having previously held roles …

June 21, 2021
GET CONNECTED
RECENT POSTS
ABOUT ME
LIFESTYLE
SHOP ONLINE
old Home - ProAxsis